Target Information

Target General Infomation
Target ID
T44682
Former ID
TTDI02341
Target Name
Interleukin-22 ligand
Gene Name
IL22
Synonyms
Cytokine Zcyto18; IL10related Tcellderivedinducible factor; ILTIF; Interleukin22; IL22
Target Type
Clinical Trial
Disease Psoriasis [ICD9: 696; ICD10: L40]
Function
Cytokine that contributes to the inflammatory response in vivo.
BioChemical Class
Cytokine: interleukin
UniProt ID
Q9GZX6
Sequence
MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA
KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP
FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI
Drugs and Mode of Action
Drug(s) Fezakinumab Drug Info Phase 2 Psoriasis [524431]
ILV-095 Drug Info Phase 1 Psoriasis [522847]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
NetPath Pathway IL9 Signaling Pathway
References
Ref 522847ClinicalTrials.gov (NCT01010542) Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects. U.S. National Institutes of Health.
Ref 524431ClinicalTrials.gov (NCT01941537) Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis. U.S. National Institutes of Health.
Ref 544277Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.